Chronic hepatitis B virus infection

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 39-54

  McMahon, Brian J ^a  

^a Liver Disease and Hepatitis Program   (United States)

Author keywords

Chronic hepatitis B; Management; Natural history

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; BLOOD DONOR; CANCER CHEMOTHERAPY; CHOLESTATIC HEPATITIS; DRUG EFFICACY; GENOTYPE; HEALTH CARE PERSONNEL; HEMODIALYSIS PATIENT; HEPATITIS B; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LEUKEMIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LYMPHOMA; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PATIENT MONITORING; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SURVIVAL RATE; VIRUS REACTIVATION;

CHRONIC HEPATITIS B; MANAGEMENT; NATURAL HISTORY;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; DNA, VIRAL; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; MONITORING, IMMUNOLOGIC; MONITORING, PHYSIOLOGIC;

EID: 84888028453     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.08.004     Document Type: Review

References (57)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. JViral Hepat 2004, 11(2):97-107.
2. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005, 25(Suppl 1):3-8.
3. Weinbaum C.M., Mast E.E., Ward J.W. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009, 49(5):S35-S44.
4. McHugh J.A., Cullison S., Apuzzio J., et al. Chronic hepatitis B infection: a workshop consensus statement and algorithm. JFam Pract 2011, 60(9):E1-E8.
5. Beasley R.P., Hwang L.Y., Lee G.C., et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2(8359):1099-1102.
6. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. JInfect Dis 1985, 151(4):599-603.
7. Bond W.W., Favero M.S., Petersen N.J., et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981, 1(8219):550-551.
8. McMahon B.J. Natural history of chronic hepatitis B. Clin Liver Dis 2009, 14(3):381-396.
9. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45(4):1056-1075.
10. McMahon B.J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009, 3(2):334-342.
11. Ahn S.H., Park Y.N., Park J.Y., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. JHepatol 2005, 42(2):188-194.
12. Liaw Y.F., Sheen I.S., Chen T.J., et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13(4):627-631.
13. Simonetti J., Bulkow L., McMahon B.J., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51(5):1531-1537.
14. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34(4):617-624.
15. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61(10):1942-1956.
16. McMahon B.J., Holck P., Bulkow L., et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, (135):759-768.
17. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(5):S45-S55.
18. Livingston S.E., Simonetti J.P., McMahon B.J., et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. JInfect Dis 2007, 195(1):5-11.
19. Yang H.I., Yeh S.H., Chen P.J., et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. JNatl Cancer Inst 2008, 100(16):1134-1143.
20. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. NEngl J Med 2002, 347(3):168-174.
21. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130(3):678-686.
22. Goldstein S.T., Zhou F.J., Hadler S.C., et al. Amathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
23. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662.
24. European Association for the Study of the Liver EASL clinical practice guidelines. Management of chronic hepatitis B European Association for the Study of the Liver. JHepatol 2011, 55:245-264.
25. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2(3):263-283.
26. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351(15):1521-1531.
27. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment withtenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381(9865):468-475.
28. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32(4 Pt 1):842-846.
29. Castera L. Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. Gastroenterology 2012, 142(6):1293-1302.e4.
30. Park S.H., Kim C.H., Kim D.J., et al. Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. JClin Gastroenterol 2011, 45(4):361-365.
31. Vallet-Pichard A., Mallet V., Nalpas B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46(1):32-36.
32. Zhang Y.G., Wang B.E., Wang T.L., et al. Assessment of hepatic fibrosis by transient elastography in patients with chronic hepatitis B. Pathol Int 2010, 60(4):284-290.
33. Castera L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a5-year prospective study of 13,369 examinations. Hepatology 2010, 51(3):828-835.
34. Fung J., Lai C.L., Cheng C., et al. Mild-to-moderate elevation of alanine amino-transferase may increase liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Hepatology 2009, 50(4):971A.
35. McMahon B.J. Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life. Gastroenterology 2010, 139(2):380-382.
36. Brunetto M.R., Olivari F., Colombatto P., et al. Use of HBsAg serum levels help to distinguish active from inactive HBV genotype D carriers. Gastroenterology 2010, 139:483-490.
37. Chan H.L., Wong V.W., Wong G.L., et al. Alongitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010, 52(4):1232-1241.
38. Sonneveld M.J., Wong V.W., Woltman A.M. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142(3):513-520.e1.
39. Hughes S.A., Wedemeyer H., Harrison P.M. Hepatitis delta virus. Lancet 2011, 378(9785):73-85.
40. Wedemeyer H., Yurdaydin C., Dalekos G.N., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. NEngl J Med 2011, 364(4):322-331.
41. Triantos C., Kalafateli M., Nikolopoulou V., et al. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012, 35(6):663-673.
42. Kourtis A.P., Bulterys M., Hu D.J., et al. HIV-HBV coinfection-a global challenge. NEngl J Med 2012, 366(19):1749-1752.
43. Thio C.L., Seaberg E.C., Skolasky R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet 2002, 360(9349):1921-1926.
44. Chun H.M., Roediger M.P., Hullsiek K.H., et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. JInfect Dis 2012, 205(2):185-193.
45. Nikolopoulos G.K., Paraskevis D., Hatzitheodorou E., et al. Impact of Hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48(12):1763-1771.
46. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 2000, 31(4):1030-1031.
47. Liaw Y.F., Chen Y.C., Sheen I.S., et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004, 126(4):1024-1029.
48. Donato F., Boffetta P., Puoti M. Ameta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75(3):347-354.
49. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49(5):S156-S165.
50. Yeo W., Chan P.K., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. JMed Virol 2000, 62(3):299-307.
51. Carroll M.B., Forgione M.A. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010, 29(9):1021-1029.
52. Leung C., Tsoi E., Burns G., et al. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 2011, 16(5):579-584.
53. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148(7):519-528.
54. Lok A.S., Ward J.W., Perrillo R.P., et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012, 156(10):743-745.
55. Buchanan C., Tran T.T. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis 2011, 15(4):753-764.
56. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
57. Holmberg S.D., Suryaprasad A., Ward J.W. Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep 2012, 61(3):1-12.